- Home
- MRSN vs ACCD Comparison
MRSN vs ACCD Comparison
Compare MRSN & ACCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- ACCD
- Stock Information
- Founded
- MRSN 2001
- ACCD 2007
- Country
- MRSN United States
- ACCD United States
- Employees
- MRSN N/A
- ACCD N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- ACCD Business Services
- Sector
- MRSN Health Care
- ACCD Consumer Discretionary
- Exchange
- MRSN Nasdaq
- ACCD Nasdaq
- Market Cap
- MRSN 252.0M
- ACCD 281.1M
- IPO Year
- MRSN 2017
- ACCD 2020
- Fundamental
- Price
- MRSN $0.62
- ACCD $6.89
- Analyst Decision
- MRSN Buy
- ACCD Buy
- Analyst Count
- MRSN 6
- ACCD 11
- Target Price
- MRSN $6.00
- ACCD $6.36
- AVG Volume (30 Days)
- MRSN 7.3M
- ACCD 3.3M
- Earning Date
- MRSN 02-26-2025
- ACCD 01-10-2025
- Dividend Yield
- MRSN N/A
- ACCD N/A
- EPS Growth
- MRSN N/A
- ACCD N/A
- EPS
- MRSN N/A
- ACCD N/A
- Revenue
- MRSN $34,837,000.00
- ACCD $446,718,000.00
- Revenue This Year
- MRSN N/A
- ACCD $14.58
- Revenue Next Year
- MRSN N/A
- ACCD $12.65
- P/E Ratio
- MRSN N/A
- ACCD N/A
- Revenue Growth
- MRSN N/A
- ACCD 14.99
- 52 Week Low
- MRSN $0.56
- ACCD $3.08
- 52 Week High
- MRSN $6.28
- ACCD $13.93
- Technical
- Relative Strength Index (RSI)
- MRSN 20.37
- ACCD 87.45
- Support Level
- MRSN $0.56
- ACCD $6.82
- Resistance Level
- MRSN $1.45
- ACCD $6.90
- Average True Range (ATR)
- MRSN 0.14
- ACCD 0.12
- MACD
- MRSN -0.06
- ACCD 0.33
- Stochastic Oscillator
- MRSN 6.49
- ACCD 99.16
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About ACCD Accolade Inc.
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.